drugset / Trial / NCT01226030
Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is dose-escalation open-label study to determine the MTD of M2ES in Subjects With Advanced Solid Tumors the recommended Phase II dose.The recommended dose and regimen of M2ES will be selected to perform the pharmacokinetic study profiles.
Timeline
- Start
- 2009-09
- Primary completion
- 2011-04
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M2ES | Protein / enzyme biologic | 7.5 mg | Intravenous |
| Subject | M2ES | Protein / enzyme biologic | 15 mg | Intravenous |
| Subject | M2ES | Protein / enzyme biologic | 30 mg | Intravenous |
| Subject | M2ES | Protein / enzyme biologic | 60 mg | Intravenous |